Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis

References

• Palumbo A, Anderson K. Multiple myeloma[J]. N Engl J Med. 2011;364(11):1046–1060. doi:10.1056/NEJMra1011442.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol. 2011;6:249–274. doi:10.1146/annurev-pathol-011110-130249.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150. doi:10.1186/s13045-020-00980-5.
   PubMed Web of Science ®Google Scholar
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563–1573. doi:10.1016/S0140-6736(20)32292-3.
   PubMed Web of Science ®Google Scholar
• Parikh K, Sekhri A, Cang S, et al. Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78. doi:10.1186/s13045-014-0078-0.
   PubMedGoogle Scholar
• Gravina G, Senapedis W, Mccauley D, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7(1):85. doi:10.1186/s13045-014-0085-1.
   PubMedGoogle Scholar
• Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155–165. doi:10.1038/leu.2013.115.
   PubMed Web of Science ®Google Scholar
• Turner JG, Dawson J, Sullivan DM, et al. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014;27:62–73. doi:10.1016/j.semcancer.2014.03.001.
   PubMed Web of Science ®Google Scholar
• Turner JG, Dawson JL, Gomez J, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016;7(48):78896–78909. doi:10.18632/oncotarget.12969.
   PubMedGoogle Scholar
• Mo CC, Jagannath S, Chari A, et al. Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol. 2021;14(8):697–706. doi: 10.1080/17474086.2021.1923473.
   PubMed Web of Science ®Google Scholar
• Chen C, Garzon R, Gutierrez M, et al. Safety, efficacy, and determination of the recommended phase 2 dose for the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330). Blood. 2015;126(5):258. doi:10.1182/blood.V126.23.258.258.
   Google Scholar
• Fu WJ, Xia ZJ, Fu CC, et al. Results of the phase 2 MARCH study: oral ATG-010 (selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI). J Clin Oncol. 2021;39(Suppl15):e20002. doi:10.1200/JCO.2021.39.15_suppl.e20002.
   Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi:10.1056/NEJMoa1903455.
   PubMed Web of Science ®Google Scholar
• Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export With oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–866. doi:10.1200/JCO.2017.75.5207.
   PubMed Web of Science ®Google Scholar
• Gasparetto C, Lipe B, Tuchman S, et al. Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients. J Clin Oncol. 2021;39(Suppl15):8038. doi:10.1200/JCO.2021.39.15_suppl.8038.
   Google Scholar
• White D, Chen C, Baljevic M, et al. Oral Selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). J Clin Oncol. 2021;39(Suppl15):8018. doi:10.1200/JCO.2021.39.15_suppl.8018.
   Google Scholar
• Gasparetto C, Lentzsch S, Schiller G, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. eJHaem. 2021;2:56–65. doi:10.1002/jha2.122.
   PubMedGoogle Scholar
• White DJ, LeBlanc R, Baljevic M, et al. Selinexor, lenalidomide and dexamethasone (SRD) for patients with relapsed/refractory and newly diagnosed multiple myeloma[J]. Blood. 2020;136(Suppl1):45–46. doi:10.1182/blood-2020-140141.
   Google Scholar
• Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–2554. doi:10.1182/blood-2018-06-858852.
   PubMed Web of Science ®Google Scholar
• Salcedo M, Lendvai N, Mastey D, et al. Phase I study of selinexor, Ixazomib, and Low-dose dexamethasone in patients With relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(3):198–200. doi:10.1016/j.clml.2019.12.013.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Jasielec JK, Rosenbaum CA, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019;186(4):549–560. doi:10.1111/bjh.15969.
   PubMed Web of Science ®Google Scholar
• Broijl A, Asselbergs E, Lonergan S, et al. A phase II study of selinexor(KPT-330) combined with bortezomib and dexamethasone (SVD) for induction and consolidation for patients with progressive or refractory multiple myeloma: The selvedex trial. HemaSphere. 2018;2(Suppl2):611–612.
   Google Scholar
• Baz R, Zonder JA, Shain KH, et al. Phase I/II study of liposomal doxorubicin (DOX) in combination with Selinexor (SEL) and dexamethasone (DEX) for relapsed and refractory multiple myeloma (RRMM)[J]. Blood. 2017;130(Suppl1):3095. doi:10.1182/blood.V130.Suppl_1.3095.3095.
   Google Scholar
• Magen H, Geva M, Volchik Y, et al. Selinexor, bortezomib, and dexamethasone for heavily pretreated multiple myeloma: A case series. Clin Lymphoma Myeloma Leuk. 2020;20(12):e947–e955. doi: 10.1016/j.clml.2020.07.016.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Otero P, González-Calle V, Sureda A, et al. Selinexor in combination with daratumumab-bortezomib and dexamethasone for the treatment of relapse or refractory multiple myeloma: initial results of the phase 2, open-label, multicenter GEM-selibordara study. Blood. 2021;138(Suppl1):1677. doi:10.1182/blood-2021-147725.
   PubMedGoogle Scholar
• Tao Y, Zhou H, Niu T. Safety and efficacy analysis of selinexor-based treatment in multiple myeloma, a meta-analysis based on prospective clinical trials. Front Pharmacol. 2021;12:758992. doi:10.3389/fphar.2021.758992.
   PubMedGoogle Scholar
• Abushanab D, Mraiche F, Al-Badriyeh D. Pcn20 efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis. Value Health. 2021;24(Suppl1):S22. doi:10.1016/j.jval.2021.04.112.
   Google Scholar
• Turner JG, Dawson JL, Meads M, et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016;9(1):73. doi:10.1186/s13045-016-0304-z.
   PubMedGoogle Scholar
• Kashyap T, Argueta C, Unger T, et al. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. Oncotarget. 2018;9(56):30773–30786. doi:10.18632/oncotarget.25637.
   PubMedGoogle Scholar
• Dolph M, Tremblay G, Gilligan AM, et al. Network meta-analysis of once weekly selinexor-bortezomib-dexamethasone in previously treated multiple myeloma. J Health Econ Outcomes Res. 2021;8(2):26–35. doi:10.36469/jheor.2021.27080.
   PubMedGoogle Scholar
• Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102(1):1–11. doi:10.1007/s00277-022-05058-5.
   PubMed Web of Science ®Google Scholar
• Baljevic M, Gasparetto C, Schiller GJ, et al. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem. 2022;3(4):1270–1276. doi:10.1002/jha2.572.
   PubMedGoogle Scholar
• Chari A, Vogl DT, Jagannath S, et al. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020;189(4):e126–e130. doi:10.1111/bjh.16550.
   PubMed Web of Science ®Google Scholar